Meeting
2023 ASCO Annual Meeting
Efficacy and safety of combining PD-1 blockage and human papillomavirus vaccine for patients with relapsed/refractory advanced cervical cancer.
Authors
Buhai Wang
Cancer Institute of Northern Jiangsu People's Hospital, Yangzhou, China
Buhai Wang , Juan J Gu , Yuechao Wu , Yichun Zeng , Yichen Liang , Liqin Liu , Yinxia Wu , Yuxiang Huang , Qiuxian Li , Caiyue Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04096911
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5530)
DOI
10.1200/JCO.2023.41.16_suppl.5530
Abstract #
5530
Poster Bd #
225
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
First Author: Hang Su
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco
Poster
2024 ASCO Annual Meeting
Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study.
First Author: Jiayong Liu
Poster
2024 ASCO Annual Meeting
Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
First Author: Stéphane De Botton